AXDX - アクセレレ―ト・ダイアグノスティックス (Accelerate Diagnostics Inc.) アクセレレ―ト・ダイアグノスティックス

 AXDXのチャート


 AXDXの企業情報

symbol AXDx
会社名 Accelerate Diagnostics Inc (アクセレレ―ト・ダイアグノスティックス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アクセレレイト・ダイアグノスティクス(Accelerate Diagnostics Inc.)は重大な感染症の診断を通じて患者のアウトカムを開発するソリューションを提供するインビトロ診断会社である。同社のin vitro診断プラットフォームであるAccelerate Phenoシステムは、生細菌または真菌細胞が特定の抗生物質に耐性かまたは感受性かを決定する抗生物質感受性試験(AST)を行うための遺伝子型技術(ID)、感染性病原体および表現型技術を利用する 。同社は単一の患者サンプルから直接病原体を検出・同定し、続いて同定結果に基づいて抗菌剤感受性試験を行う。Accelerate PhenoTest BCキットは、高い罹患率と死亡リスクを伴う生命を脅かす状態である菌血症または真菌血症の疑いのある患者に、IDとASTの結果を提供する。Accelerate Phenoシステムは、ウォークアウェイの自動化を特長とし、固定計測器と一回使用のテストキットで構成される。   アクセレレ―ト・ダイアグノスティックスは米国で医療診断機器を製造、販売。「ID/ASTシステム」の名前で感染性病原体の同定と薬剤感受性試験向け機器、検査キットを提供。敗血症と呼吸器感染などの診断のためにグラム陽性菌とグラム陰性菌の抗生物質への感受性を検査。   Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.
本社所在地 3950 South Country Club Road Suite 470 Tucson AZ 85714 USA
代表者氏名 John Patience ジョン・ペイシェンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-863-8088
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 239人
url www.acceleratediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/axdx
adr_tso
EBITDA EBITDA(百万ドル) -72.46400
終値(lastsale) 18.4197
時価総額(marketcap) 997021337.403
時価総額 時価総額(百万ドル) 974.57450
売上高 売上高(百万ドル) 5.44000
企業価値(EV) 企業価値(EV)(百万ドル) 892.66950
当期純利益 当期純利益(百万ドル) -77.40700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Accelerate Diagnostics Inc revenues increased from $1.2M to $2.5M. Net loss increased 44% to $44M. Revenues reflect Domestic(United States) segment increase of 71% to $1.8M Foreign-World ex-United States (Region) segment increase from $167K to $678K. Higher net loss reflects Other Sales general and administrative increase of 48% to $23.2M (expense).

 AXDXのテクニカル分析


 AXDXのニュース

   Accelerate Diagnostics Announces Virtual Product Demo Day and Schedules Call to Review Third Quarter 2020 Results  2020/10/12 13:05:00 PR Newswire
TUCSON, Ariz., Oct. 12, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it will host a virtual Investor Product Demo Day for investors and analysts on Tuesday, October 20, 2020 at 11:00 a.m. Eastern Time. The event will include an inside look at the Company's…
   Antimicrobial Susceptibility Testing Market 2020 Analysis : bioMérieux SA, Danaher, BD, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Liofilchem S.r.l., Accelerate Diagnostics, Inc  2020/09/28 18:31:43 OpenPR
Global Antimicrobial Susceptibility Testing Market, By Product (Automated Laboratory Instruments, Susceptibility Testing Disks), Methods (Dilution, Disk Diffusion, E-test & Others), Type (Antibacterial Testing, Antifungal Testing), Application (Clinical Diagnostics, Epidemiology), End User (Diagnostic Centers and Hospitals, Pharmaceutical and Biotechnology Companies, Contract
   Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements  2020/09/16 13:00:00 PR Newswire
TUCSON, Ariz., Sept. 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and…
   Accelerate Diagnostics announces FDA emergency use nod for individual COVID-19 tests (NASDAQ:AXDX)  2020/09/10 13:38:07 Seeking Alpha
Accelerate Diagnostics (AXDX +0.3%) announces FDA emergency use authorization (EUA) for BioCheck's individual SARS-CoV-2 IgM and IgG Test Kits; the announc
   Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer  2020/08/24 13:15:00 PR Newswire
TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Nedal Safwat has been appointed Chief Strategy Officer. Dr. Safwat joins Accelerate from BioMerieux, the world's leading microbiology diagnostics company. Jack Phillips, President…
   Antimicrobial Susceptibility Testing Market 2020 Analysis : bioMérieux SA, Danaher, BD, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Liofilchem S.r.l., Accelerate Diagnostics, Inc  2020/09/28 18:31:43 OpenPR
Global Antimicrobial Susceptibility Testing Market, By Product (Automated Laboratory Instruments, Susceptibility Testing Disks), Methods (Dilution, Disk Diffusion, E-test & Others), Type (Antibacterial Testing, Antifungal Testing), Application (Clinical Diagnostics, Epidemiology), End User (Diagnostic Centers and Hospitals, Pharmaceutical and Biotechnology Companies, Contract
   Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements  2020/09/16 13:00:00 PR Newswire
TUCSON, Ariz., Sept. 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and…
   Accelerate Diagnostics announces FDA emergency use nod for individual COVID-19 tests (NASDAQ:AXDX)  2020/09/10 13:38:07 Seeking Alpha
Accelerate Diagnostics (AXDX +0.3%) announces FDA emergency use authorization (EUA) for BioCheck's individual SARS-CoV-2 IgM and IgG Test Kits; the announc
   Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer  2020/08/24 13:15:00 PR Newswire
TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Nedal Safwat has been appointed Chief Strategy Officer. Dr. Safwat joins Accelerate from BioMerieux, the world's leading microbiology diagnostics company. Jack Phillips, President…
   Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing  2020/08/19 07:58:30 Smarter Analyst
Shares in Accelerate Diagnostics surged almost 10% in extended market trading after the company said the US Food and Drug Administration (FDA) granted … The post Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing appeared first on Smarter Analyst .
   Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer  2020/08/24 13:15:00 PR Newswire
TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Nedal Safwat has been appointed Chief Strategy Officer. Dr. Safwat joins Accelerate from BioMerieux, the world's leading microbiology diagnostics company. Jack Phillips, President…
   Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing  2020/08/19 07:58:30 Smarter Analyst
Shares in Accelerate Diagnostics surged almost 10% in extended market trading after the company said the US Food and Drug Administration (FDA) granted … The post Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing appeared first on Smarter Analyst .
   Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering  2020/08/06 20:15:00 PR Newswire
TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2020. "While the progress of new contracts and go-lives continued to be slowed by the effects of the pandemic, utilization within…
   Accelerate Diagnostics Schedules Call to Review Second Quarter 2020 Results  2020/07/16 12:00:00 PR Newswire
TUCSON, Ariz., July 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern Time to review 2020 second quarter financial results. To listen to the audio webcast online, visit ir.axdx….
   How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry  2020/05/26 12:51:00 Zacks Investment Research
Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アクセレレ―ト・ダイアグノスティックス AXDX Accelerate Diagnostics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)